LIPOCINE RSS Feed | Nachrichten - www.finanzen.netwww.finanzen.net bietet Finanznachrichten zum weltweiten BörsengeschehenFinanzenhttps://www.finanzen.netde-definanzen.net GmbHFri, 10 Apr 2026 19:17:17 +0200https://images.finanzen.net/images/finanzen_net_neu.gifLIPOCINE RSS Feed | Nachrichten - www.finanzen.nethttps://www.finanzen.netLipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)Mon, 12 Jan 2026 14:00:00 +0100https://www.finanzen.net/nachricht/aktien/lipocine-reports-encouraging-progress-post-second-interim-safety-review-in-phase-3-trial-of-lpcn-1154-in-postpartum-depression-ppd-15409046
  • Company on track to report topline results early in the second quarter of 2026
  • Second planned Data and Safety Monitoring Board (DSMB) meeting evaluated all available safety data for the ...

    ]]>https://www.finanzen.net/nachricht/aktien/lipocine-reports-encouraging-progress-post-second-interim-safety-review-in-phase-3-trial-of-lpcn-1154-in-postpartum-depression-ppd-15409046Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment MilestoneTue, 16 Dec 2025 14:00:00 +0100https://www.finanzen.net/nachricht/aktien/lipocine-s-ppd-phase-3-study-lpcn-1154-hits-80-enrollment-milestone-15361789
    • Second Drug Safety Monitoring Board (DSMB) meeting update planned for mid-January 2026
    • Topline results on track for the second quarter of 2026

    ]]>https://www.finanzen.net/nachricht/aktien/lipocine-s-ppd-phase-3-study-lpcn-1154-hits-80-enrollment-milestone-15361789Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)Tue, 18 Nov 2025 14:00:00 +0100https://www.finanzen.net/nachricht/aktien/lipocine-highlights-promising-interim-safety-profile-in-phase-3-trial-of-lpcn-1154-in-postpartum-depression-ppd-15287779

    • Per the Drug Safety Monitoring Board (DSMB) meeting evaluating one-third of planned participants, study to continue as planned
    • More than half of planned participants have completed dosing ...

      ]]>https://www.finanzen.net/nachricht/aktien/lipocine-highlights-promising-interim-safety-profile-in-phase-3-trial-of-lpcn-1154-in-postpartum-depression-ppd-15287779Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025Thu, 06 Nov 2025 14:00:00 +0100https://www.finanzen.net/nachricht/aktien/lipocine-announces-financial-results-for-the-third-quarter-ended-september-30-2025-15207627

      SALT LAKE CITY, Nov. 6, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company ...

      ]]>      https://www.finanzen.net/nachricht/aktien/lipocine-announces-financial-results-for-the-third-quarter-ended-september-30-2025-15207627      Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®Tue, 04 Nov 2025 14:00:00 +0100https://www.finanzen.net/nachricht/aktien/lipocine-presents-lpcn-2401-clinical-data-at-obesityweek-15185288

      SALT LAKE CITY, Nov. 4, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company ...

      ]]>      https://www.finanzen.net/nachricht/aktien/lipocine-presents-lpcn-2401-clinical-data-at-obesityweek-15185288